COMMUNIQUÉS West-GlobeNewswire

Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares
23/09/2025
VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Heartflow Announces FDA 510(k) Clearance and Launch of Next Generation Heartflow Plaque Analysis Platform
22/09/2025
AI-Powered Heartflow Plaque Analysis to be Covered by Cigna Health Plans Nationwide MOUNTAIN VIEW, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for [...]
ArriVent Appoints Brent S. Rice as Chief Commercial Officer
22/09/2025
NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative [...]
J-Star Holding Names Sam Van as Chief Executive Officer
22/09/2025
TAICHUNG CITY, Taiwan, Sept. 22, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of [...]
Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update
22/09/2025
Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of the First Subject into Cohort 2 of the BB-301 Phase 1b/2a Treatment Study Expected in Q4 2025 [...]
GENFIT : Résultats financiers du premier semestre 2025 et point sur les activités de la Société
22/09/2025
Trésorerie et équivalents de trésorerie s’élevant à 107,5 millions d’euros au 30 juin 2025 n’incluant pas le paiement d’étape de 26,5 millions d’euros facturé en mai 2025 (reçu en juillet 2025) à la suite de l' [...]
GENFIT Reports First-Half 2025 Financial Results and Provides Corporate Update
22/09/2025
Cash and cash equivalents totaled €107.5 million as of June 30, 2025, excluding the €26.5 million milestone invoiced in May 2025 (received in July 2025) upon pricing and reimbursement approval of Iqirvo® (elafibranor) [...]
MBX Biosciences Announces Proposed Public Offering
22/09/2025
CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the [...]
BetaGlue Therapeutics annonce la nomination d’Alexis Peyroles au poste de directeur général
22/09/2025
MILAN, 22 sept. 2025 (GLOBE NEWSWIRE) -- BetaGlue ® Therapeutics (« BetaGlue » ou la « Société »), une entreprise d’oncologie en phase clinique développant une plateforme innovante de radiothérapie pour le traitement [...]
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
22/09/2025
ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
Fortrea Appoints William Sharbaugh to Board of Directors
22/09/2025
DURHAM, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the appointment of William Sharbaugh to the Company’s Board [...]
AMN Healthcare Announces Pricing of Senior Notes Offering
22/09/2025
DALLAS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), announced today that its wholly owned subsidiary, AMN Healthcare, Inc., priced its previously announced private offering of $400.0 [...]
MEDIA ADVISORY - Protests Against Ford Government’s Expanding Hospital Privatization Plans
22/09/2025
TORONTO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- “The Ford government is privatizing our public hospitals in a move that is costing patients thousands of dollars and taking away from our local public hospital services. [...]
The Sentinel Introduces Transformative Approach to Healing in British Columbia, Setting a New Standard in Integrative Care
22/09/2025
KASLO, BC, Sept. 22, 2025 (GLOBE NEWSWIRE) -- The Sentinel , a leading wellness centre, today announced a major initiative advancing the integration of traditional healing practices with contemporary therapeutic [...]
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination
22/09/2025
Semnur’s shares of common stock and warrants are expected to continue to trade on the OTC Markets under the ticker symbols “SMNR” and “SMNRW”, respectively. Scilex (together with its affiliates) owns approximately 87.5 [...]
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
22/09/2025
Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for [...]
Until Labs Announces $58M Series A Funding Round, to Develop an Organ Cryopreservation Product for Transplant Patients and Surgeons
22/09/2025
This investment, led by Founders Fund with participation from Lux Capital and Field Ventures, brings total investment to date to $100M+, and will be used to build out the team and operational infrastructure SAN [...]
Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares
22/09/2025
VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
InBrain Pharma to Present Long-Term Follow-Up Clinical Data from Its Phase I/II DIVE-I Trial in Parkinson’s Disease at the MDS 2025 Conference
22/09/2025
InBrain Pharma to Present Long-Term Follow-Up Clinical Data from Its Phase I/II DIVE-I Trial in Parkinson’s Disease at the MDS 2025 Conference Lille, September 22, 2025 – InBrain Pharma, a company specialized in the [...]

Pages